Other languages Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Market Closed - Canadian Securities Exchange Other stock markets 01:23:32 2024-04-26 pm EDT			5-day change	1st Jan Change
0.03 ^CAD	+20.00%		0.00%	0.00%

Apr. 23	FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	MT
Apr. 23	Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	Apr. 18
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	Apr. 02
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	Mar. 27
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	Mar. 19
Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 28
Revive Therapeutics Explores the Use of Bucillamine for Long COVID	Feb. 01
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada	Jan. 16
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine	Jan. 10
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of A Novel Lyophilized Formulation of Bucillamine	Dec. 18
Revive Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 28
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development	Nov. 21
Revive Therapeutics Ltd.?s Newly-Formed Subsidiary, Revive Diagnostics Inc. Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize Novel Long COVID Rapid Test	Nov. 06
Revive Therapeutics Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-26
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure	23-10-17
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development	23-10-11
Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development	23-08-22
Revive Therapeutics Ltd. Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents	23-07-28
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19	23-07-06
Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19	23-05-30
Revive Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Other languages

Filters